Novel systemic therapies for breast cancer are being rapidly implemented into clinical practice. These drugs often have different mechanisms of action and side-effect profiles compared with traditional chemotherapy. Underpinning practice-changing clinical trials focused on the systemic therapies under investigation, thus there are sparse data available on radiotherapy. Integration of these new systemic therapies with radiotherapy is therefore challenging. Given this rapid, transformative change in breast cancer multimodal management, the multidisciplinary community must unite to ensure optimal, safe, and equitable treatment for all patients. The aim of this collaborative group of radiation, clinical, and medical oncologists, basic and translational scientists, and patient advocates was to: scope, synthesise, and summarise the literature on integrating novel drugs with radiotherapy for breast cancer; produce consensus statements on drug-radiotherapy integration, where specific evidence is lacking; and make best-practice recommendations for recording of radiotherapy data and quality assurance for subsequent studies testing novel drugs.

International multidisciplinary consensus on the integration of radiotherapy with new systemic treatments for breast cancer: European Society for Radiotherapy and Oncology (ESTRO)-endorsed recommendations / Meattini, Icro; Becherini, Carlotta; Caini, Saverio; Coles, Charlotte E; Cortes, Javier; Curigliano, Giuseppe; de Azambuja, Evandro; Isacke, Clare M; Harbeck, Nadia; Kaidar-Person, Orit; Marangoni, Elisabetta; Offersen, Birgitte V; Rugo, Hope S; Salvestrini, Viola; Visani, Luca; Morandi, Andrea; Lambertini, Matteo; Poortmans, Philip; Livi, Lorenzo. - In: THE LANCET ONCOLOGY. - ISSN 1474-5488. - ELETTRONICO. - 25:(2024), pp. 0-0. [10.1016/S1470-2045(23)00534-X]

International multidisciplinary consensus on the integration of radiotherapy with new systemic treatments for breast cancer: European Society for Radiotherapy and Oncology (ESTRO)-endorsed recommendations

Meattini, Icro
;
Becherini, Carlotta;Caini, Saverio;Salvestrini, Viola;Visani, Luca;Morandi, Andrea;Livi, Lorenzo
2024

Abstract

Novel systemic therapies for breast cancer are being rapidly implemented into clinical practice. These drugs often have different mechanisms of action and side-effect profiles compared with traditional chemotherapy. Underpinning practice-changing clinical trials focused on the systemic therapies under investigation, thus there are sparse data available on radiotherapy. Integration of these new systemic therapies with radiotherapy is therefore challenging. Given this rapid, transformative change in breast cancer multimodal management, the multidisciplinary community must unite to ensure optimal, safe, and equitable treatment for all patients. The aim of this collaborative group of radiation, clinical, and medical oncologists, basic and translational scientists, and patient advocates was to: scope, synthesise, and summarise the literature on integrating novel drugs with radiotherapy for breast cancer; produce consensus statements on drug-radiotherapy integration, where specific evidence is lacking; and make best-practice recommendations for recording of radiotherapy data and quality assurance for subsequent studies testing novel drugs.
2024
25
0
0
Meattini, Icro; Becherini, Carlotta; Caini, Saverio; Coles, Charlotte E; Cortes, Javier; Curigliano, Giuseppe; de Azambuja, Evandro; Isacke, Clare M; ...espandi
File in questo prodotto:
File Dimensione Formato  
2024_Meattini et al_Lancet Oncol_Consensus RT-drug breast.pdf

accesso aperto

Tipologia: Pdf editoriale (Version of record)
Licenza: Open Access
Dimensione 351.76 kB
Formato Adobe PDF
351.76 kB Adobe PDF

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/1353992
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 6
  • ???jsp.display-item.citation.isi??? ND
social impact